RxDoctor Payments Data

Jeffrey Fontenot, MD

Internal Medicine · Broussard, LANPI 1346744570

Payments from drug & device makers

$931in general payments, 2019–2025

Across 49 payments — averaging $19.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$193
  • Exact Sciences$187
  • Pfizer$115
  • AbbVie$95
  • Novartis$82
  • Lilly USA, LLC$74
  • plus $186 from 7 others

What the payments were for

  • Food & beverage$931100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$931 in reported general payments places this provider in the 60th percentile of 1,528 internal medicine providers in Louisiana.

See all internal medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$67,321
Medicare patients
184
Services billed
728

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide102$105,246
JardianceEmpagliflozin59$61,899
MounjaroTirzepatide50$52,607
FarxigaDapagliflozin Propanediol28$26,584
TrulicityDulaglutide16$26,515
TradjentaLinagliptin23$23,699
EliquisApixaban18$15,106
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$11,430
EntrestoSacubitril/Valsartan12$8,416
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog13$7,312
MovantikNaloxegol Oxalate16$6,330
Xigduo XrDapaglifloz Propaned/Metformin12$5,929
Lantus SolostarInsulin Glargine,hum.Rec.Anlog36$4,253
SymbicortBudesonide/Formoterol Fumarate12$3,245
Novolog FlexpenInsulin Aspart15$2,477

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$193$105,246102 claims
Boehringer IngelheimJardiance, Tradjenta$17$85,59982 claims
Lilly USA, LLCMounjaro, Trulicity$74$79,12266 claims
AstraZenecaFarxiga, Symbicort$32$29,83040 claims
PfizerEliquis$115$15,10618 claims
GSKTrelegy Ellipta$22$11,43018 claims
NovartisEntresto$82$8,41612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,528 internal medicine providers in Louisiana.

Other internal medicine in Broussard

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →